Approval · Notice of Compliance 18003 · 2016
COSENTYX: Notice of Compliance 18003
Issued April 20, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18003
- Date
- April 20, 2016
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: cosentyx is indicated for the treatment of adult patients with active psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. cosentyx can be used alone or in combination with methotrexate
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COSENTYX | Not yet assigned | — |
Medicinal ingredients
- SECUKINUMAB 150 MG per 1ML